Umecrine Cognition submits application for Phase 2 clinical trial of golexanolone
STOCKHOLM – May 19, 2022. Umecrine Cognition AB today announces that the company has submitted a clinical trial application (CTA) for a Phase 2 study of golexanolone in patients with primary…